Velardi, E
Dudakov, J A
van den Brink, M R M
Article History
First Online: 3 June 2015
Competing interests
: Professor MRMvdB has received consulting or advisory fees from Merck & Co, Yobira Therapeutics, Boehringer Ingelheim, and has received lecture fees from Merck & Co, Novartis Pharma A.G., Novartis Institute for Biomedical Research, Tobira Therapeutics, Boehringer Ingelheim and Regeneron Pharmaceuticals. He has also received grant support from Radiation Effects Research Foundation (RERF), NIH/NHLBI, NIH/NCI, NIH/NIAID and the European Consortium. The remaining authors declare no conflicts of interest.